Global law firm Freshfields has advised CICC as sole sponsor and financial adviser to Sunshine Lake Pharma in relation to Sunshine Lake Pharma’s privatisation of HKSE-listed YiChang HEC Changjiang Pharmaceutical by way of merger by absorption and the concurrent listing of the H shares of Sunshine Lake Pharma by way of introduction on the HKSE.

Sunshine Lake Pharma is a vertically integrated pharmaceutical company engaging in research and development, production and commercialisation of pharmaceutical products. They strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology.

The Freshfields team advising on the listing was led by partners Richard Wang, Howie Farn and David Yi. They were supported by counsel Quan Zhou, senior associates Chongming Ma, associates Frank Fan and Zhanqi Xu, US legal manager Ruoyu Xiong, and legal consultant Murphy Yi, Yuxin Lei and Eric Tang.

The Freshfields team advising on the privatisation was led by partner Sarah Su and was supported by senior associate Kelly Huang and associate Liam Li.